LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Fjodorova, Marija
Languages: English
Types: Doctoral thesis
Subjects: Q1

Classified by OpenAIRE into

mesheuropmc: nervous system
The work discussed in this thesis adds further knowledge regarding the survival of embryonic dopaminergic grafts, derived from the rat ventral mesencephalon, in the rat model of Parkinson’s disease, in terms of the populations of cells involved, their distribution within the grafts, and how these are affected by the donor age and the host environment in to which they are implanted.\ud The current data further reinforce the notion that harvesting ventral mesencephalic tissue at embryonic day 12 (E12) before the peak of dopamine neurogenesis yields more dopamine cells in the grafts and, more importantly, also yields more nigral A9 type dopamine neurons, which are an important determinant for functional recovery.\ud Following on from this, commitment of dopamine neural precursor cells to the two dopamine neuron phenotypes, and how this is affected by the host environment was investigated, by grafting rat E12 and E14 ventral mesencephalon tissue into different cerebral targets. Brain regions were chosen that receive either the nigral A9 type dopamine, ventral tegmental A10 type dopamine or noradrenaline innervation. The yield of A9 type dopamine neurons was found to be influenced both by the environment within the graft and by the host environment in the transplantation site to a higher extent than the yield of A10 type dopamine neurons. \ud Dopaminergic progenitors procured from rat embryos at E12 were shown to have a greater potential to proliferate post-grafting and differentiate into mature dopamine neurons as compared to embryos at E14. In vivo proliferation of younger precursor cells significantly contributed to the higher yields of the A9 type dopamine neurons in the grafts. If this improved yield of the A9 type dopamine neurons could be reproduced in human trials, fewer human donors might suffice to produce functional grafts in Parkinson’s disease patients.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • FREEMAN, T. B., OLANOW, C. W., HAUSER, R. A., NAUERT, G. M., SMITH, D. A., BORLONGAN, C. V., SANBERG, P. R., HOLT, D. A., KORDOWER, J. H., VINGERHOETS, J. G., SNOW, B. J., CALNE, D. & GAUGER, L. I. 1995a. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinsons-disease. Annals of Neurology, 38, 379-388.
    • FREEMAN, T. B., SANBERG, P. R., NAUERT, G. M., BOSS, B. D., SPECTOR, D., OLANOW, C. W. & KORDOWER, J. H. 1995b. The influence of donor age on the survival of solid and suspension intraparenchymal human embryonic nigral grafts. Cell Transplantation, 4, 141-154.
    • FREEMAN, T. B., SPENCE, M. S., BOSS, B. D., SPECTOR, D. H., STRECKER, R. E., OLANOW, C. W. & KORDOWER, J. H. 1991. Development of dopaminergic-neurons in the human substantia-nigra. Experimental Neurology, 113, 344-353.
    • FREUND, T. F., BOLAM, J. P., BJORKLUND, A., STENEVI, U., DUNNETT, S. B., POWELL, J. F. & SMITH, A. D. 1985. Efferent synaptic connections of grafted dopaminergic-neurons reinnervating the host neostriatum - a tyrosinehydroxylase immunocytochemical study. Journal of Neuroscience, 5, 603-616.
    • FRICKER, R. A., CARPENTER, M. K., WINKLER, C., GRECO, C., GATES, M. A. & BJORKLUND, A. 1999. Site-specific migration and neuronal differentiation of human neural progenitor cells after transplantation in the adult rat brain. J Neurosci, 19, 5990-6005.
    • FUNAYAMA, M., HASEGAWA, K., KOWA, H., SAITO, M., TSUJI, S. & OBATA, F. 2002. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Annals of Neurology, 51, 296-301.
    • GALVIN, J. E., POLLACK, J. & MORRIS, J. C. 2006. Clinical phenotype of Parkinson disease dementia. Neurology, 67, 1605-1611.
    • GASPAR, P., BERGER, B., ALVAREZ, C., VIGNY, A. & HENRY, J. P. 1985. Catecholaminergic innervation of the septal area in man - immunocytochemical study using TH and DBH antibodies. Journal of Comparative Neurology, 241, 12-33.
    • GASPAR, P., BERGER, B., FEBVRET, A., VIGNY, A., KRIEGER-POULET, M. & BORRI-VOLTATTORNI, C. 1987. Tyrosine hydroxylase-immunoreactive neurons in the human cerebral cortex: a novel catecholaminergic group? Neuroscience Letters, 80, 257-62.
    • GATES, M. A., COUPE, V. M., TORRES, E. M., FRICKER-GATES, R. A. & DUNNETT, S. B. 2004. Spatially and temporally restricted chemoattractive and chemorepulsive cues direct the formation of the nigro-striatal circuit. European Journal of Neuroscience, 19, 831-844.
    • GATES, M. A., TORRES, E. M., WHITE, A., FRICKER-GATES, R. A. & DUNNETT, S. B. 2006. Re-examining the ontogeny of substantia nigra dopamine neurons. European Journal of Neuroscience, 23, 1384-1390.
    • GELB, D. J., OLIVER, E. & GILMAN, S. 1999. Diagnostic criteria for Parkinson disease. Archives of Neurology, 56, 33-39.
    • GERFEN, C. R., ENGBER, T. M., MAHAN, L. C., SUSEL, Z., CHASE, T. N., MONSMA, F. J. & SIBLEY, D. R. 1990. D1 and D2 dopamine receptor regulated gene-expression of striatonigral and striatopallidal neurons. Science, 250, 1429-1432.
    • GERFEN, C. R., HERKENHAM, M. & THIBAULT, J. 1987. The neostriatal mosaic. II. patch-directed and matrix-directed mesostriatal dopaminergic and nondopaminergic systems. The Journal of Neuroscience, 7, 3915-34.
    • GERLACH, M., DESSER, H., YOUDIM, M. B. J. & RIEDERER, P. 1996. New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline. Journal of Neural Transmission Supplement, 48, 7-21.
    • GERLACH, M., RIEDERER, P., PRZUNTEK, H. & YOUDIM, M. B. H. 1991. MPTP mechanisms of neurotoxicity and their implications for Parkinsons-disease. European Journal of Pharmacology-Molecular Pharmacology Section, 208, 273-286.
    • GERMAN, D. C. & MANAYE, K. F. 1993. Midbrain dopaminergic-neurons (nuclei a8, a9, and a10) - 3-dimensional reconstruction in the rat. Journal of Comparative Neurology, 331, 297-309.
    • GERMAN, D. C., NELSON, E. L., LIANG, C. L., SPECIALE, S. G., SINTON, C. M. & SONSALLA, P. K. 1996. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration, 5, 299-312.
    • GIASSON, B. I., DUDA, J. E., MURRAY, I. V. J., CHEN, Q. P., SOUZA, J. M., HURTIG, H. I., ISCHIROPOULOS, H., TROJANOWSKI, J. Q. & LEE, V. M. Y. 2000. Oxidative damage linked to neurodegeneration by selective alphasynuclein nitration in synucleinopathy lesions. Science, 290, 985-989.
    • GIASSON, B. I., DUDA, J. E., QUINN, S. M., ZHANG, B., TROJANOWSKI, J. Q. & LEE, V. M. Y. 2002. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron, 34, 521-533.
    • GIBB, W. R. G. & LEES, A. J. 1989. The significance of the Lewy Body in the diagnosis of idiopathic Parkinsons-disease. Neuropathology and Applied Neurobiology, 15, 27-44.
    • GIBB, W. R. G. & LEES, A. J. 1991. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia-nigra, and differential cell-death in Parkinsonsdisease. Journal of Neurology Neurosurgery and Psychiatry, 54, 388-396.
    • GILADI, N., MCDERMOTT, M. P., FAHN, S., PRZEDBORSKI, S., JANKOVIC, J., STERN, M., TANNER, C. & PARKINSON STUDY, G. 2001. Freezing of gait in PD - Prospective assessment in the DATATOP cohort. Neurology, 56, 1712- 1721.
    • GLINKA, Y., GASSEN, M. & YOUDIM, M. B. H. 1997. Mechanism of 6- hydroxydopamine neurotoxicity. Journal of Neural Transmission-Supplement, 55-66.
    • GOETZ, C. G., NUTT, J. G. & STEBBINS, G. T. 2008. The Unified Dyskinesia Rating Scale: Presentation and Clinimetric Profile. Movement Disorders, 23, 2398- 2403.
    • GOETZ, C. G., STEBBINS, G. T., KLAWANS, H. L., KOLLER, W. C., GROSSMAN, R. G., BAKAY, R. A. E. & PENN, R. D. 1991. United-Parkinson-Foundation neurotransplantation registry on adrenal-medullary transplants - presurgical, and 1-year and 2-year follow-up. Neurology, 41, 1719-1722.
    • GOOD, P. F., HSU, A., WERNER, P., PERL, D. P. & OLANOW, C. W. 1998. Protein nitration in Parkinson's disease. Journal of Neuropathology and Experimental Neurology, 57, 338-342.
    • GOSSEL, M., SCHMIDT, W. J., LOSCHER, W., ZAJACZKOWSKI, W. & DANYSZ, W. 1995. Effect of coadministration of glutamate-receptor antagonists and dopaminergic agonists on locomotion in monoamine-depleted rats. Journal of Neural Transmission-Parkinsons Disease and Dementia Section, 10, 27-39.
    • GRAFF-RADFORD, J., FOOTE, K. D., RODRIGUEZ, R. L., FERNANDEZ, H. H., HAUSER, R. A., SUDHYADHOM, A., ROSADO, C. A., SANCHEZ, J. C. & OKUN, M. S. 2006. Deep brain stimulation of the internal segment of the globus pallidus in delayed runaway dyskinesia. Arch Neurol, 63, 1181-4.
    • GRANT, R. J. & CLARKE, P. B. S. 2002. Susceptibility of ascending dopamine projections to 6-hydroxydopamine in rats: Effect of hypothermia. Neuroscience, 115, 1281-1294.
    • GREALISH, S., JONSSON, M. E., LI, M., KIRIK, D., BJORKLUND, A. & THOMPSON, L. H. 2010. The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease. Brain, 133, 482-495.
    • GREENE, J. G., DINGLEDINE, R. & GREENAMYRE, J. T. 2005. Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism. Neurobiology of Disease, 18, 19-31.
    • GREFFARD, S., VERNY, M., BONNET, A.-M., SEILHEAN, D., HAUW, J.-J. & DUYCKAERTS, C. 2010. A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death. Neurobiology of Aging, 31, 99-103.
    • GRIMM, J., MUELLER, A., HEFTI, F. & ROSENTHAL, A. 2004. Molecular basis for catecholaminergic neuron diversity. Proceedings of the National Academy of Sciences of the United States of America, 101, 13891-13896.
    • HABER, S. N. 2003. The primate basal ganglia: parallel and integrative networks. Journal of Chemical Neuroanatomy, 26, 317-330.
    • HAGELL, P., PICCINI, P., BJORKLUND, A., BRUNDIN, P., REHNCRONA, S., WIDNER, H., CRABB, L., PAVESE, N., OERTEL, W. H., QUINN, N., BROOKS, D. J. & LINDVALL, O. 2002. Dyskinesias following neural transplantation in Parkinson's disease. Nature Neuroscience, 5, 627-628.
    • HAGELL, P., SCHRAG, A., PICCINI, P., JAHANSHAHI, M., BROWN, R., REHNCRONA, S., WIDNER, H., BRUNDIN, P., ROTHWELL, J. C., ODIN, P., WENNING, G. K., MORRISH, P., GUSTAVII, B., BJORKLUND, A., BROOKS, D. J., MARSDEN, C. D., QUINN, N. P. & LINDVALL, O. 1999. Sequential bilateral transplantation in Parkinson's disease - Effects of the second graft. Brain, 122, 1121-1132.
    • HAHN, M., TIMMER, M. & NIKKHAH, G. 2009. Survival and Early Functional Integration of Dopaminergic Progenitor Cells Following Transplantation in a Rat Model of Parkinson's Disease. Journal of Neuroscience Research, 87, 2006- 2019.
    • HALLIDAY, G., TRINIDAD HERRERO, M., MURPHY, K., MCCANN, H., ROSBERNAL, F., BARCIA, C., MORI, H., BLESA, F. J. & OBESO, J. A. 2009. No Lewy Pathology in Monkeys with Over 10 Years of Severe MPTP Parkinsonism. Movement Disorders, 24, 1519-1523.
    • HAMILTON, D. 2012. Clinical and academic transplantation in Paris. A History of Organ Transplantation. 1st edition ed.: University of Pittsburgh Pre.
    • HAYES, L., ZHANG, Z., ALBERT, P., ZERVAS, M. & AHN, S. 2011. Timing of Sonic Hedgehog and Gli1 Expression Segregates Midbrain Dopamine Neurons. Journal of Comparative Neurology, 519, 3001-3018.
    • HAYES, N. L. & NOWAKOWSKI, R. S. 2000. Exploiting the dynamics of S-phase tracers in developing brain: Interkinetic nuclear migration for cells entering versus leaving the S-phase. Developmental Neuroscience, 22, 44-55.
    • HAYES, N. L. & NOWAKOWSKI, R. S. 2002. High doses of bromodeoxyuridine increase number of labeled cells in adult mouse dentate gyrus by decreasing tracer loading time. Society for Neuroscience Abstract Viewer and Itinerary Planner, 2002, Abstract No. 126.3-Abstract No. 126.3.
    • HEIKKILA, R. E., SHAPIRO, B. S. & DUVOISIN, R. C. 1981. The relationship between loss of dopamine nerve-terminals, striatal H-3 spiroperidol binding and rotational behavior in unilaterally 6-hydroxydopamine-lesioned rats. Brain Research, 211, 285-292.
    • HEIKKILA, R. E. & SONSALLA, P. K. 1992. The MPTP-treated mouse as a model of parkinsonism - how good is it. Neurochemistry International, 20, S299-S303.
    • HELY, M. A., MORRIS, J. G. L., REID, W. G. J. & TRAFFICANTE, R. 2005. Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Movement Disorders, 20, 190-199.
    • HENDRY, I. A. 1975. Retrograde trans-synaptic control of development of cholinergic terminals in sympathetic-ganglia. Brain Research, 86, 483-487.
    • HERTZMAN, C., WIENS, M., BOWERING, D., SNOW, B. & CALNE, D. 1990. Parkinsons-disease - a case-control study of occupational and environmental risk-factors. American Journal of Industrial Medicine, 17, 349-355.
    • HERZOG, J., POGARELL, O., PINSKER, M. O., KUPSCH, A., OERTEL, W. H., LINDVALL, O., DEUSCHL, G. & VOLKMANN, J. 2008. Deep brain stimulation in Parkinson's disease following fetal nigral transplantation. Mov Disord, 23, 1293-6.
    • HEUER, A., LELOS, M. J., KELLY, C. M., TORRES, E. M. & DUNNETT, S. B. 2013a. Dopamine-rich grafts alleviate deficits in contralateral response space induced by extensive dopamine depletion in rats. Experimental Neurology, 247, 485-495.
    • HEUER, A., NGOC-NGA, V. & DUNNETT, S. B. 2013b. Behavioural recovery on simple and complex tasks by means of cell replacement therapy in unilateral 6- hydroxydopamine-lesioned mice. European Journal of Neuroscience, 37, 1691- 1704.
    • HIRSCH, E. C., GRAYBIEL, A. M., DUYCKAERTS, C. & JAVOYAGID, F. 1987. Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proceedings of the National Academy of Sciences of the United States of America, 84, 5976-5980.
    • HUGHES, A. J., DANIEL, S. E., BLANKSON, S. & LEES, A. J. 1993. A clinicopathological study of 100 cases of Parkinsons-disease. Archives of Neurology, 50, 140-148.
    • HUNG, H. C. & LEE, E. H. Y. 1998. MPTP produces differential oxidative stress and antioxidative responses in the nigrostriatal and mesolimbic dopaminergic pathways. Free Radical Biology and Medicine, 24, 76-84.
    • HURD, Y. L., PRISTUPA, Z. B., HERMAN, M. M., NIZNIK, H. B. & KLEINMAN, J. E. 1994. The dopamine transporter and dopamine-D-2 receptor messengerRNAs are differentially expressed in limbic-related and motor-related subpopulations of human mesencephalic neurons. Neuroscience, 63, 357-362.
    • ILINSKY, I. A., KULTASILINSKY, K. & SMITH, K. R. 1982. Organization of basal ganglia inputs to the thalamus - a light and electron-microscopic study in the cat. Applied Neurophysiology, 45, 230-237.
    • INDEN, M., KITAMURA, Y., ABE, M., TAMAKI, A., TAKATA, K. & TANIGUCHI, T. 2011. Parkinsonian Rotenone Mouse Model: Reevaluation of Long-Term Administration of Rotenone in C57BL/6 Mice. Biological & Pharmaceutical Bulletin, 34, 92-96.
    • INDEN, M., KITAMURA, Y., TAKEUCHI, H., YANAGIDA, T., TAKATA, K., KOBAYASHI, Y., TANIGUCHI, T., YOSHIMOTO, K., KANEKO, M., OKUMA, Y., TAIRA, T., ARIGA, H. & SHIMOHAMA, S. 2007. Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. Journal of Neurochemistry, 101, 1491-1504.
    • IRAVANI, M. M., SYED, E., JACKSON, M. J., JOHNSTON, L. C., SMITH, L. A. & JENNER, P. 2005. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets. European Journal of Neuroscience, 21, 841-854.
    • JANKOVIC, J. 2008. Parkinson's disease: clinical features and diagnosis. Journal of Neurology Neurosurgery and Psychiatry, 79, 368-376.
    • JAVITCH, J. A., DAMATO, R. J., STRITTMATTER, S. M. & SNYDER, S. H. 1985. Parkinsonism-inducing neurotoxin, n-methyl-4-phenyl-1,2,3,6- tetrahydropyridine - uptake of the metabolite n-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proceedings of the National Academy of Sciences of the United States of America, 82, 2173-2177.
    • JIANG, H., JACKSONLEWIS, V., MUTHANE, U., DOLLISON, A., FERREIRA, M., ESPINOSA, A., PARSONS, B. & PRZEDBORSKI, S. 1993. Adenosine receptor antagonists potentiate dopamine receptor agonist-induced rotational behavior in 6-hydroxydopamine-lesioned rats. Brain Research, 613, 347-351.
    • JOKSIMOVIC, M., YUN, B. A., KITTAPPA, R., ANDEREGG, A. M., WCHANG, W., TAKETO, M. M., MCKAY, R. D. G. & AWATRAMANI, R. B. 2009. Wnt antagonism of Shh facilitates midbrain floor plate neurogenesis. Nature Neuroscience, 12, 125-131.
    • JONSSON, M. E., ONO, Y., BJORKLUND, A. & THOMPSON, L. H. 2009. Identification of transplantable dopamine neuron precursors at different stages of midbrain neurogenesis. Experimental Neurology, 219, 341-354.
    • KATZENSCHLAGER, R., HEAD, J., SCHRAG, A., BEN-SHLOMO, Y., EVANS, A., LEES, A. J. & PARKINSON'S DIS RES GRP UNITED, K. 2008. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology, 71, 474-480.
    • KAUFMAN, M. P., LONGHURST, J. C., RYBICKI, K. J., WALLACH, J. H. & MITCHELL, J. H. 1983. Effects of static muscular-contraction on impulse activity of group-iii and group-iv afferents in cats. Journal of Applied Physiology, 55, 105-112.
    • KAY, D. M., FACTOR, S. A., SAMII, A., HIGGINS, D. S., GRIFFITH, A., ROBERTS, J. W., LEIS, B. C., NUTT, J. G., MONTIMURRO, J. S., KEEFE, R. G., ATKINS, A. J., YEAROUT, D., ZABETIAN, C. P. & PAYAMI, H. 2008. Genetic Association Between alpha-Synuclein and Idiopathic Parkinson's Disease. American Journal of Medical Genetics Part B-Neuropsychiatric Genetics, 147B, 1222-1230.
    • KELE, J., SIMPLICIO, N., FERRI, A. L. M., MIRA, H., GUILLEMOT, F., ARENAS, E. & ANG, S. L. 2006. Neurogenin 2 is required for the development of ventral midbrain dopaminergic neurons. Development, 133, 495-505.
    • KELLY, C. M., PRECIOUS, S. V., TORRES, E. M., HARRISON, A. W., WILLIAMS, D., SCHERF, C., WEYRAUCH, U. M., LANE, E. L., ALLEN, N. D., PENKETH, R., AMSO, N. N., KEMP, P. J., DUNNETT, S. B. & ROSSER, A. E. 2011. Medical Terminations of Pregnancy: A Viable Source of Tissue for Cell Replacement Therapy for Neurodegenerative Disorders. Cell Transplantation, 20, 503-513.
    • KIM, H.-J., SUGIMORI, M., NAKAFUKU, M. & SVENDSEN, C. N. 2007. Control of neurogenesis and tyrosine hydroxylase expression in neural progenitor cells through bHLH proteins and Nurr1. Experimental Neurology, 203, 394-405.
    • KIRIK, D., GEORGIEVSKA, B., BURGER, C., WINKLER, C., MUZYCZKA, N., MANDEL, R. J. & BJORKLUND, A. 2002. Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAVmediated gene transfer. Proceedings of the National Academy of Sciences of the United States of America, 99, 4708-4713.
    • KISH, S. J., SHANNAK, K. & HORNYKIEWICZ, O. 1988. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinsons-disease - pathophysiologic and clinical implications. New England Journal of Medicine, 318, 876-880.
    • KITADA, T., ASAKAWA, S., HATTORI, N., MATSUMINE, H., YAMAMURA, Y., MINOSHIMA, S., YOKOCHI, M., MIZUNO, Y. & SHIMIZU, N. 1998. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 392, 605-608.
    • KOHLER, C., EVERITT, B. J., PEARSON, J. & GOLDSTEIN, M. 1983. Immunohistochemical evidence for a new group of catecholamine-containing neurons in the basal forebrain of the monkey. Neuroscience Letters, 37, 161- 166.
    • KOLB, B., PEDERSEN, B., BALLERMANN, M., GIBB, B. & WHISHAW, I. Q. 1999. Embryonic and postnatal injections of bromodeoxyuridine produce agedependent morphological and behavioral abnormalities. Journal of Neuroscience, 19, 2337-2346.
    • KORDOWER, J. H., CHU, Y. P., HAUSER, R. A., FREEMAN, T. B. & OLANOW, C. W. 2008a. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nature Medicine, 14, 504-506.
    • KORDOWER, J. H., CHU, Y. P., HAUSER, R. A., OLANOW, C. W. & FREEMAN, T. B. 2008b. Transplanted Dopaminergic Neurons Develop PD Pathologic Changes: A Second Case Report. Movement Disorders, 23, 2303-2306.
    • KORDOWER, J. H., FREEMAN, T. B., CHEN, E. Y., MUFSON, E. J., SANBERG, P. R., HAUSER, R. A., SNOW, B. & OLANOW, C. W. 1998. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Movement Disorders, 13, 383-393.
    • KORDOWER, J. H., GOETZ, C. G., FREEMAN, T. B. & OLANOW, C. W. 1997a. Dopaminergic transplants in patients with Parkinson's disease: Neuroanatomical correlates of clinical recovery. Experimental Neurology, 144, 41-46.
    • KORDOWER, J. H., KANAAN, N. M., CHU, Y., BABU, R. S., STANSELL, J., III, TERPSTRA, B. T., SORTWELL, C. E., STEECE-COLLIER, K. & COLLIER, T. J. 2006. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Annals of Neurology, 60, 264-268.
    • KORDOWER, J. H., ROSENSTEIN, J. M., COLLIER, T. J., BURKE, M. A., CHEN, E. Y., LI, J. M., MARTEL, L., LEVEY, A. E., MUFSON, E. J., FREEMAN, T. B. & OLANOW, C. W. 1996. Functional fetal nigral grafts in a patient with Parkinson's disease: Chemoanatomic, ultrastructural, and metabolic studies. Journal of Comparative Neurology, 370, 203-230.
    • KORDOWER, J. H., STYREN, S., CLARKE, M., DEKOSKY, S. T., OLANOW, C. W. & FREEMAN, T. B. 1997b. Fetal grafting for Parkinson's disease: expression of immune markers in two patients with functional fetal nigral implants. Cell Transplant, 6, 213-9.
    • KOTKOVA, P. & WEISS, P. 2013. Psychiatric factors related to sexual functioning in patients with Parkinson's disease. Clinical Neurology and Neurosurgery, 115, 419-424.
    • KRACK, P., BENAZZOUZ, A., POLLAK, P., LIMOUSIN, P., PIALLAT, B., HOFFMANN, D., XIE, J. & BENABID, A. L. 1998. Treatment of tremor in Parkinson's disease by subthalamic nucleus stimulation. Movement Disorders, 13, 907-914.
    • KRAMER, M. L. & SCHULZ-SCHAEFFER, W. J. 2007. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. Journal of Neuroscience, 27, 1405-1410.
    • KRAYENBUHL, H. & YASARGIL, M. G. 1960. Bilateral thalamotomy in parkinsonism. Journal of Nervous and Mental Disease, 130, 538-541.
    • KRAYENBUHL, H., YASARGIL, M. G. & WYSS, O. A. M. 1961. Bilateral thalamotomy and pallidotomy as treatment for bilateral parkinsonism. Journal of Neurosurgery, 18, 429-&.
    • KRIKS, S., SHIM, J.-W., PIAO, J., GANAT, Y. M., WAKEMAN, D. R., XIE, Z., CARRILLO-REID, L., AUYEUNG, G., ANTONACCI, C., BUCH, A., YANG, L., BEAL, M. F., SURMEIER, D. J., KORDOWER, J. H., TABAR, V. & STUDER, L. 2011. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature, 480, 547-U177.
    • KRISS, J. P. & REVESZ, L. 1962. Distribution and fate of bromodeoxyuridine and bromodeoxycytidine in mouse and rat. Cancer Research, 22, 254-&.
    • KRUGER, R., KUHN, W., MULLER, T., WOITALLA, D., GRAEBER, M., KOSEL, S., PRZUNTEK, H., EPPLEN, J. T., SCHOLS, L. & RIESS, O. 1998. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nature Genetics, 18, 106-108.
    • KUAN, W. L., LIN, R., TYERS, P. & BARKER, R. A. 2007. The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias. Neurobiology of Disease, 25, 594-608.
    • KUUSISTO, E., PARKKINEN, L. & ALAFUZOFF, I. 2003. Morphogenesis of Lewy bodies: Dissimilar incorporation of alpha-synuclein, ubiquitin, and p62. Journal of Neuropathology and Experimental Neurology, 62, 1241-1253.
    • LACEY, M. G., MERCURI, N. B. & NORTH, R. A. 1987. Dopamine acts on D2 receptors to increase potassium conductance in neurons of the rat substantianigra zona compacta. Journal of Physiology-London, 392, 397-416.
    • LADER, M. 2008. Antiparkinsonian medication and pathological gambling. Cns Drugs, 22, 407-416.
    • LAMMEL, S., HETZEL, A., HAECKEL, O., JONES, I., LISS, B. & ROEPER, J. 2008. Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system. Neuron, 57, 760-773.
    • LANDMESSER, L. 1978. Interactions between neurons and their targets during invivo synaptogenesis. Federation Proceedings, 37.
    • LANG, A. E. & LOZANO, A. M. 1998. Parkinson's disease - Second of two parts. New England Journal of Medicine, 339, 1130-1143.
    • LANGSTON, J. W., BALLARD, P., TETRUD, J. W. & IRWIN, I. 1983. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 219, 979-980.
    • LANGSTON, J. W., FORNO, L. S., REBERT, C. S. & IRWIN, I. 1984. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6- tetrahydropyrine (MPTP) in the squirrel-monkey. Brain Research, 292, 390-394.
    • LASAK, J. M. & GORECKI, J. P. 2009. The History of Stereotactic Radiosurgery and Radiotherapy. Otolaryngologic Clinics of North America, 42, 593-599.
    • LEE, K. H., CHANG, S. Y., ROBERTS, D. W. & KIM, U. 2004. Neurotransmitter release from high-frequency stimulation of the subthalamic nucleus. Journal of Neurosurgery, 101, 511-517.
    • LEES, A. J., HARDY, J. & REVESZ, T. 2009. Parkinson's disease. Lancet, 373, 2055- 2066.
    • Parkinson's Disease During Duodopa Therapy. Movement Disorders, 24, 2293- 2294.
    • MANN, D. M. A. & YATES, P. O. 1983. Pathological basis for neurotransmitter changes in Parkinsons-disease. Neuropathology and Applied Neurobiology, 9, 3- 19.
    • MAO, L. M., LAU, Y. S., PETROSKE, E. & WANG, J. Q. 2001. Profound astrogenesis in the striatum of adult mice following nigrostriatal dopaminergic lesion by repeated MPTP administration. Developmental Brain Research, 131, 57-65.
    • MARCHAND, R. & POIRIER, L. J. 1983. Isthmic origin of neurons of the rat substantia-nigra. Neuroscience, 9, 373-381.
    • MARIES, E., KORDOWER, J. H., CHU, Y., COLLIER, T. J., SORTWELL, C. E., OLARU, E., SHANNON, K. & STEECE-COLLIER, K. 2006. Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. Neurobiol Dis, 21, 165-80.
    • MARSDEN, C. D. 1994. Problems with long-term levodopa therapy for Parkinsonsdisease. Clinical Neuropharmacology, 17, S32-S44.
    • MARTINAT, C., SHENDELMAN, S., JONASON, A., LEETE, T., BEAL, M. F., YANG, L. C., FLOSS, T. & ABELIOVICH, A. 2004. Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: An ES-derived cell model of primary Parkinsonism. Plos Biology, 2, 1754-1763.
    • MARUYAMA, W., TAKAHASHI, T., YOUDIM, M. & NAOI, M. 2002. The antiparkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. Journal of Neural Transmission, 109, 467-481.
    • MASLIAH, E., ROCKENSTEIN, E., VEINBERGS, I., MALLORY, M., HASHIMOTO, M., TAKEDA, A., SAGARA, Y., SISK, A. & MUCKE, L. 2000. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders. Science, 287, 1265-1269.
    • MASLIAH, E., ROCKENSTEIN, E., VEINBERGS, I., SAGARA, Y., MALLORY, M., HASHIMOTO, M. & MUCKE, L. 2001. beta-Amyloid peptides enhance alphasynuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 98, 12245-12250.
    • MCCORMACK, A. L., ATIENZA, J. G., LANGSTON, J. W. & DI MONTE, D. A. 2006. Decreased susceptibility to oxidative stress underlies the resistance of specific dopaminergic cell populations to paraquat-induced degeneration. Neuroscience, 141, 929-937.
    • MCCORMACK, A. L., THIRUCHELVAM, M., MANNING-BOG, A. B., THIFFAULT, C., LANGSTON, J. W., CORY-SLECHTA, D. A. & DI MONTE, D. A. 2002. Environmental risk factors and Parkinson's disease: Selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiology of Disease, 10, 119-127.
    • MCDONALD, H. Y. & WOJTOWICZ, J. M. 2005. Dynamics of neurogenesis in the dentate gyrus of adult rats. Neuroscience Letters, 385, 70-75.
    • MCDONNELL, S. K., SCHAID, D. J., ELBAZ, A., STRAIN, K. J., BOWER, J. H., AHLSKOG, J. E., MARAGANORE, D. M. & ROCCA, W. A. 2006. Complex segregation analysis of Parkinson's disease: The Mayo Clinic family study. Annals of Neurology, 59, 788-795.
    • MENDEZ, I., DAGHER, A., HONG, M., GAUDET, P., WEERASINGHE, S., MCALISTER, V., KING, D., DESROSIERS, J., DARVESH, S., ACORN, T. & ROBERTSON, H. 2002. Simultaneous intrastriatal and intranigral fetal
  • Inferred research data

    The results below are discovered through our pilot algorithms. Let us know how we are doing!

    Title Trust
    62
    62%
  • No similar publications.

Share - Bookmark

Funded by projects

  • WT

Cite this article